NERV Minerva Neurosciences, Inc.

NEUTRAL Impact: 4/10 DEFA14A
Horizon days Filed Apr 23, 2026 Processed 1mo ago SEC 0001193125-26-171805
Proxy solicitation materials
Latest settled — T+20d
NERV ▼ -26.35% at T+20d
NEUTRAL call ✗ call lost -26.35% · α vs SPY -30.99% · entry $6.83 → $5.03
Next anchor: T+60d in 6w
Currently $4.74 · -30.60% from $6.83 entry
Entry anchored
Apr 22, 03:59 PM ET
via Databento tick
T+1d
-3.73%
call -3.73% · α -4.52%
$6.58
settled 7w ago
T+5d
-6.44%
call -6.44% · α -7.92%
$6.39
settled 6w ago
T+20d
-26.35%
call -26.35% · α -30.99%
$5.03
settled 20d ago
T+60d
call — · α —
in 6w

Price Chart

Loading chart...

Executive Summary

Minerva Neurosciences, Inc. (NERV) filed a definitive proxy statement (DEFA14A) for its 2026 Annual Meeting, disclosing key governance matters including director elections, executive compensation, and auditor ratification. This filing follows a recent settlement agreement with former President Geoff Race, which may influence shareholder sentiment and voting behavior on the proposed board nominees and compensation matters.

Actionable Insight

Monitor the shareholder vote on June 3, 2026, particularly on director elections and executive compensation, as the recent settlement with the former president may influence voting outcomes.

Key Facts

  • The filing is a definitive proxy statement (DEFA14A) for Minerva Neurosciences' 2026 Annual Meeting.
  • Proposals include electing two Class III directors (David Kupfer and Jan van Heek), approving amendments to the company's certificate of incorporation, approving executive compensation, and ratifying the auditor.
  • The filing is preceded by a settlement agreement (8-K) with former President Geoff Race, which included a termination payment and waiver of claims.
  • The meeting date is June 3, 2026, with a vote deadline of June 2, 2026.

Financial Impact

The settlement with Geoff Race involved a termination payment, but the specific amount is not disclosed in the provided documents.

compensationdilution

Risk Factors

  • The settlement with the former president could lead to shareholder scrutiny of board decisions and executive compensation.
  • The proposed amendments to the certificate of incorporation may face opposition if not clearly communicated.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-171805
Document: 0001193125-26-171805-index-headers.html0001193125-26-171805
Document: 0001193125-26-171805-index.html0001193125-26-171805
Document: 0001193125-26-171805.txt0001193125-26-171805
7 reports for NERV
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for NERV — sortable, filterable
Type Now
May 27, 2026
13d ago
8-K
BEARISH ★ 6/10
$5.00 $4.78▲ +4.40%▲ +4.72%$4.74 (+5.20%)
May 5, 2026
5w ago
8-K
NEUTRAL ★ 4/10
$6.25 $5.63▼ −9.92%▼ −11.90%$4.74 (−24.16%)
Apr 23, 2026
6w ago
DEFA14A
NEUTRAL ★ 4/10
$6.83 $6.39▼ −6.44%▼ −7.92%$4.74 (−30.60%)
Mar 25, 2026
10w ago
Press Release
NEUTRAL ★ 5/10
$6.14 $5.28▼ −14.01%▼ −15.64%$4.74 (−22.80%)
Mar 20, 2026
11w ago
EFFECT
NEUTRAL ★ 4/10
$7.54 $6.18▼ −18.04%▼ −15.89%$4.74 (−37.14%)
Mar 11, 2026
12w ago
S-3
BEARISH ★ 7/10
$7.30 $7.78▼ −6.58%▼ −8.76%$4.74 (+35.07%)
Mar 11, 2026
12w ago
Press Release
MIXED ★ 6/10
$7.30 $7.78▲ +6.58%▲ +8.76%$4.74 (−35.07%)
Showing 7 of 7

US Market Status

Market Closed — Opens Thu (9h 36m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access